Crystal structure of streptavidin mutant with low immunogenicity

Journal of Bioscience and Bioengineering

Volumn 119, Issue 6, 2015, Pages 642-647

  Kawato, Tatsuya ^a   Mizohata, Eiichi ^a   Meshizuka, Tomohiro ^a   Doi, Hirofumi ^b   Kawamura, Takeshi ^b   Matsumura, Hiroyoshi ^a   Yumura, Kyohei ^c   Tsumoto, Kouhei ^c   Kodama, Tatsuhiko ^b   Inoue, Tsuyoshi ^a   Sugiyama, Akira ^c  

^a OSAKA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

B factor; Crystal structure; Low immunogenicity; Pre targeting; Protein engineering; Streptavidin; X ray structural analysis

Indexed keywords

BINDING ENERGY; BINDING SITES; PROTEINS; STRUCTURAL ANALYSIS; X RAYS;

B FACTORS; IMMUNOGENICITY; PRE-TARGETING; PROTEIN ENGINEERING; STREPTAVIDIN; X RAY STRUCTURAL ANALYSIS;

CRYSTAL STRUCTURE;

BIOTIN; MUTANT PROTEIN; STREPTAVIDIN; TETRAMER; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; HYDROGEN BOND; IMMUNOGENICITY; PROCEDURES; PROTEIN FUNCTION; SUBSTITUTION REACTION; WILD TYPE; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

AMINO ACID SUBSTITUTION; BIOTIN; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; STREPTAVIDIN;

EID: 84928955693     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2014.10.025     Document Type: Article

References (40)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Lu C., Hassan H.T. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. Leuk. Res. 2006, 30:296-302.
3. Reichert J.M., Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 2007, 6:349-356.
4. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J.Clin. Oncol. 2006, 24:823-834.
5. Boerman O.C., van Schaijk F.G., Oyen W.J., Corstens F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J.Nucl. Med. 2003, 44:400-411.
6. Palanca-Wessels M.C., Press O.W. Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 2014, 123:2293-2301.
7. Goodwin D., Meares C., Diamanti C., McCall M., Lai C., Torti F., McTigue M., Martin B. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur. J. Nucl. Med. 1984, 9:209-215.
8. Press O.W., Corcoran M., Subbiah K., Hamlin D.K., Wilbur D.S., Johnson T., Theodore L., Yau E., Mallett R., Meyer D.L., Axworthy D. Acomparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001, 98:2535-2543.
9. Pagel J.M., Hedin N., Subbiah K., Meyer D., Mallet R., Axworthy D., Theodore L.J., Wilbur D.S., Matthews D.C., Press O.W. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003, 101:2340-2348.
10. Pantelias A., Pagel J.M., Hedin N., Saganic L., Wilbur S., Hamlin D.K., Wilbur D.S., Lin Y., Stone D., Axworthy D., Gopal A.K., Press O.W. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 2007, 109:4980-4987.
11. Axworthy D.B., Reno J.M., Hylarides M.D., Mallett R.W., Theodore L.J., Gustavson L.M., Su F., Hobson L.J., Beaumier P.L., Fritzberg A.R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 2000, 97:1802-1807.
12. Zhang M., Zhang Z., Garmestani K., Schultz J., Axworthy D.B., Goldman C.K., Brechbiel M.W., Carrasquillo J.A., Waldmann T.A. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA 2003, 100:1891-1895.
13. Green N.M. Avidin. Adv. Protein Chem. 1975, 29:85-133.
14. Chaiet L., Wolf F.J. The properties of streptavidin, a biotin-binding protein produced by streptomycetes. Arch. Biochem. Biophys. 1964, 106:1-5.
15. Diamandis E.P., Christopoulos T.K. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin. Chem. 1991, 37:625-636.
16. Voss S., Skerra A. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng. 1997, 10:975-982.
17. Korndorfer I.P., Skerra A. Improved affinity of engineered streptavidin for the Strep-tag II peptide is due to a fixed open conformation of the lid-like loop at the binding site. Protein Sci. 2002, 11:883-893.
18. Schmidt T.G., Skerra A. The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat. Protoc. 2007, 2:1528-1535.
19. Forero A., Weiden P.L., Vose J.M., Knox S.J., LoBuglio A.F., Hankins J., Goris M.L., Picozzi V.J., Axworthy D.B., Breitz H.B., other 4 authors Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004, 104:227-236.
20. Paganelli G., Chinol M., Maggiolo M., Sidoli A., Corti A., Baroni S., Siccardi A.G. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur. J. Nucl. Med. 1997, 24:350-351.
21. Meyer D.L., Schultz J., Lin Y., Henry A., Sanderson J., Jackson J.M., Goshorn S., Rees A.R., Graves S.S. Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci. 2001, 10:491-503.
22. Forster G.J., Santos E.B., Smith-Jones P.M., Zanzonico P., Larson S.M. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J.Nucl. Med. 2006, 47:140-149.
23. Subramanian N., Adiga P.R. Mapping the common antigenic determinants in avidin and streptavidin. Biochem. Mol. Biol. Int. 1997, 43:375-382.
24. Kodama T., Hamakubo T., Sugiyama A., Tsumoto K. Hypo-immunogenic streptavidin and use thereof. International Patent Application, WO/2010/095455 2010.
25. Yumura K., Ui M., Doi H., Hamakubo T., Kodama T., Tsumoto K., Sugiyama A. Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci. 2013, 22:213-221.
26. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J.Appl. Crystallogr. 2007, 40:658-674.
27. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 1994, 50:760-763.
28. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
29. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997, 53:240-255.
30. Weber P.C., Wendoloski J.J., Pantoliano M.W., Salemme F.R. Crystallographic and thermodynamic comparison of natural and synthetic ligands bound to streptavidin. J.Am. Chem. Soc. 1992, 114:3197-3200.
31. Pahler A., Hendrickson W.A., Kolks M.A., Argarana C.E., Cantor C.R. Characterization and crystallization of core streptavidin. J.Biol. Chem. 1987, 262:13933-13937.
32. Freitag S., Le Trong I., Klumb L., Stayton P.S., Stenkamp R.E. Structural studies of the streptavidin binding loop. Protein Sci. 1997, 6:1157-1166.
33. Hyre D.E., Le Trong I., Merritt E.A., Eccleston J.F., Green N.M., Stenkamp R.E., Stayton P.S. Cooperative hydrogen bond interactions in the streptavidin-biotin system. Protein Sci. 2006, 15:459-467.
34. Hyre D.E., Le Trong I., Freitag S., Stenkamp R.E., Stayton P.S. Ser45 plays an important role in managing both the equilibrium and transition state energetics of the streptavidin-biotin system. Protein Sci. 2000, 9:878-885.
35. Le Trong I., Wang Z., Hyre D.E., Lybrand T.P., Stayton P.S., Stenkamp R.E. Streptavidin and its biotin complex at atomic resolution. Acta Crystallogr. D Biol. Crystallogr. 2011, 67:813-821.
36. Hytonen V.P., Maatta J.A., Niskanen E.A., Huuskonen J., Helttunen K.J., Halling K.K., Nordlund H.R., Rissanen K., Johnson M.S., Salminen T.A., other 3 authors Structure and characterization of a novel chicken biotin-binding protein A (BBP-A). BMC Struct. Biol. 2007, 7:8.
37. Baugh L., Le Trong I., Cerutti D.S., Mehta N., Gulich S., Stayton P.S., Stenkamp R.E., Lybrand T.P. Second-contact shell mutation diminishes streptavidin-biotin binding affinity through transmitted effects on equilibrium dynamics. Biochemistry 2012, 51:597-607.
38. Karplus P.A., Schulz G.E. Prediction of chain flexibility in proteins. Naturwissenschaften 1985, 72:212-213.
39. Baker H. Assessment of biotin status: clinical implications. Ann. N. Y. Acad. Sci. 1985, 447:129-132.
40. Knox S.J., Goris M.L., Tempero M., Weiden P.L., Gentner L., Breitz H., Adams G.P., Axworthy D., Gaffigan S., Bryan K., other 4 authors Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 2000, 6:406-414.